Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="370702"/>
<meta>
<versionId value="2"/>
<lastUpdated value="2025-05-28T13:34:35.405Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-comparator-definition"/>
</meta>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
<valueMarkdown
value="Glucagon Hydrochloride Solution (Active Comparator) [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370702. Revised 2025-05-28. Available at: https://fevir.net/resources/Group/370702. Computable resource at: https://fevir.net/resources/Group/370702#json."/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper, MD, MSPH"/>
</valueContactDetail>
</extension>
<url value="https://fevir.net/resources/Group/370702"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="urn:ietf:rfc:3986"/>
<value value="https://fevir.net/FOI/370702"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<title value="Glucagon Hydrochloride Solution (Active Comparator)"/>
<status value="active"/>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<description
value="Example of ConceptualExposureDefinition combining M11 IGBJ Protocol Example Eligibility Criteria PLUS exposure to Glucagon Hydrochloride Solution"/>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<type value="person"/>
<membership value="conceptual"/>
<combinationMethod value="all-of"/>
<characteristic>
<code>
<text value="Member of"/>
</code>
<valueReference>🔗
<reference value="Group/267506"/>
<type value="Group"/>
<display value="M11 IGBJ Protocol Example Eligibility Criteria"/>
</valueReference>
<exclude value="false"/>
<description
value="Member of M11 IGBJ Protocol Example Eligibility Criteria"/>
</characteristic>
<characteristic>
<code>
<text value="assigned to"/>
</code>
<valueCodeableConcept>
<text
value="Glucagon Hydrochloride Solution (Active Comparator) A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)"/>
</valueCodeableConcept>
<exclude value="false"/>
<description value="assigned to Glucagon Hydrochloride Solution"/>
</characteristic>
</Group>